Investors Buy Large Volume of Bristol Myers Squibb Call Options (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) saw unusually large options trading activity on Tuesday. Stock investors acquired 53,552 call options on the stock. This represents an increase of approximately 135% compared to the typical daily volume of 22,749 call options.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Institutional Trading of Bristol Myers Squibb

A number of institutional investors and hedge funds have recently modified their holdings of BMY. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $25,000. Physician Wealth Advisors Inc. boosted its holdings in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the last quarter. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Bayban acquired a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the 4th quarter worth approximately $32,000. 76.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on BMY shares. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. HSBC boosted their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $61.31.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Unusual options activity points to rising bullish interest, with investors buying 53,552 call options on Bristol Myers Squibb, well above the normal volume. This can signal expectations for further upside.
• Positive Sentiment: Recent market commentary highlighted BMY as a strong value and momentum name, reinforcing the view that investors see the stock as attractively priced relative to its earnings and cash flow profile. Article Title
• Positive Sentiment: Analyst-style coverage also noted BMY as a stock that has recently outperformed the broader market, which may be helping sentiment around the shares. Article Title
• Positive Sentiment: Another article framed Bristol Myers Squibb as a “hidden gem” for dividend-focused investors, underscoring its appeal as a defensive, income-producing healthcare name.
• Neutral Sentiment: An article discussed proposed Medicare drug price negotiation updates and the potential risk to pharma companies like BMY, but it did not present a clear near-term catalyst or a company-specific development. Article Title
• Negative Sentiment: Broader media coverage of “unpopular stocks with questionable fundamentals” may be weighing on sentiment across the sector, although the piece is not specifically centered on Bristol Myers Squibb.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock traded down $0.75 during trading hours on Tuesday, hitting $57.81. The stock had a trading volume of 5,600,211 shares, compared to its average volume of 12,469,192. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The stock has a market capitalization of $118.06 billion, a price-to-earnings ratio of 16.24, a PEG ratio of 0.16 and a beta of 0.24. The stock’s fifty day moving average is $57.05 and its two-hundred day moving average is $57.36. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts predict that Bristol Myers Squibb will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.